Molnupiravir Does Not Induce Mutagenesis in Host Lung Cells during SARS-CoV-2 Treatment

Abstract excerpt

As SARS-CoV-2 continues to evolve and spread with the emergence of new variants, interest in small molecules with broad-spectrum antiviral activity has grown. One such molecule, Molnupiravir (MOV; other names: MK-4482, EIDD-2801), a ribonucleoside analogue, has emerged as an effective SARS-CoV-2 treatment by inducing catastrophic viral mutagenesis during replication. However, there are growing concerns as MOV's...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Bacteriophages and microbial interactions
• Share to Plant Virus Research Studies
• Share to SARS-CoV-2 and COVID-19 Research